Search clinical trials for: ineligible to cisplatin

Total 474630 results

University of Texas Southwestern Medical Center
Astellas Pharma Inc

Not yet recruiting

Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer (STAR-EV)

Bladder Cancer
Zhujiang Hospital

Recruiting

RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

China
Yuanquan Yang
Gateway for Cancer Research

Not yet recruiting

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
Dana-Farber Cancer Institute
EMD Serono; National Comprehensive Cancer Network

Recruiting

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Bladder Cancer | Urothelial Carcinoma | Metastatic Bladder Cancer | Unresectable Bladder Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Metastatic Malignancy

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Portugal, Romania, Spain, Switzerland, Netherlands, P... and more
Emory University
Astex Pharmaceuticals, Inc.

Recruiting

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Head and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...

United States
The Methodist Hospital Research Institute
Pfizer

Recruiting

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE)

Urothelial Carcinoma Bladder

United States
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
Mamta Parikh
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial Carcinoma

United States
University of Alabama at Birmingham

Not yet recruiting

Chemo-embolization for Head and Neck Cancer

Squamous Cell Carcinoma | SCCHN

United States
Henan Cancer Hospital

Recruiting

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Bladder Cancer | Urothelial Carcinoma

China
Dana-Farber Cancer Institute
Pfizer

Recruiting

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Bladder Cancer | Muscle Invasive Bladder Cancer

United States
Merck Sharp & Dohme LLC
Seagen Inc.; Astellas Pharma Global Development, Inc.

Active, not recruiting

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Urinary Bladder Cancer, Muscle-invasive

Canada, United States, Australia, Belgium, France, Hungary, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Thailand, Ukraine, Argentina, Colombia, Denmark, Germany, Ireland, Israel, Japan, Malaysia, Philippines, Sing... and more
Matthew Galsky
Bristol-Myers Squibb; Hoosier Cancer Research Network

Completed

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

United States
University of Utah
Exelixis

Active, not recruiting

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

Bladder Cancer | Metastatic Urothelial Carcinoma

United States
University of Kansas Medical Center
National Center for Advancing Translational Sciences (NCATS)

Active, not recruiting

Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

Bladder Cancer

United States
Jason R. Brown
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Active, not recruiting

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Bladder Cancer | Urothelial Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Gilead Sciences

Active, not recruiting

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Metastatic Urothelial Carcinoma

United States
Incyte Corporation

Terminated

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma (Optimus)

Urothelial Carcinoma

United States, France, Italy
H. Lee Moffitt Cancer Center and Research Institute
CG Oncology, Inc.; Richard M. Shulze Family Foundation

Active, not recruiting

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China
SCRI Development Innovations, LLC
Celgene

Terminated

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Bladder Cancer | Urothelial Carcinoma

United States
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Korea, Republic of, Spain, France, Germany, Italy, Japan, Netherlands
Nabil Adra
Genentech, Inc.; Indiana University School of Medicine

Terminated

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Urothelial Carcinoma

United States
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)

Neoplasm Metastasis | Urinary Bladder Neoplasm

United States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
AIO-Studien-gGmbH

Terminated

Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers (ELDORANDO)

Cancer of Head and Neck

Germany
Arjun Balar, MD
Hoosier Cancer Research Network; Roche-Genentech

Terminated

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Urothelial Carcinoma

United States
PrECOG, LLC.
Bristol-Myers Squibb

Completed

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807)

Bladder Cancer

United States
Janssen Research & Development, LLC

Completed

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Urinary Bladder Neoplasms

United States, Spain
Monika Joshi, MD
Pfizer; Eisai Inc.; Big Ten Cancer Research Consortium

Terminated

A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

Metastatic Urothelial Cell Cancer

United States
Incyte Corporation

Terminated

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma

Spain, France, United States, Italy, Japan, Ireland, Slovakia, Austria, Belgium, Canada, Finland, Germany, Poland, Portugal, Romania, United Kingdom
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

UC (Urothelial Cancer)

United States, France, Belgium, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Australia, Netherlands, Japan, Germany, Ukraine, Canada, Ireland, Italy, Poland, Russian Federation
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Japan, Spain, Taiwan, Korea, Republic of, France, Poland, Russian Federation, Turkey
Latin American Cooperative Oncology Group

Terminated

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Bladder Cancer | Urothelial Carcinoma

Brazil
University Hospital Inselspital, Berne
AstraZeneca

Terminated

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin (NITIMIB)

Muscle-invasive Bladder Cancer

Switzerland
Matthew Galsky
Novartis Pharmaceuticals; Hoosier Cancer Research Network

Terminated

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Urothelial Carcinoma | Bladder Carcinoma

United States
Genentech, Inc.

Terminated

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

Urothelial Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Belgium
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Terminated

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Bladder Cancer

United States
Pierre Fabre Medicament

Completed

JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin (JASINT1)

Bladder Transitional Cell Carcinoma Stage IV

France
Bristol-Myers Squibb

Completed

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Transitional Cell Carcinoma | Bladder Cancer | Metastasis

United States, Korea, Republic of, United Kingdom, Spain, Australia, France, Thailand, Denmark, Poland, Belgium, Italy, Philippines, Canada, Russian Federation, Greece, Indonesia
Peking University Third Hospital
Jilin Provincial Tumor Hospital; Affiliated Hospital of Hebei University; Hebei...

Not yet recruiting

Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.

Cervical Cancer
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Ductal Adenocarcinoma

United States
Zhejiang Cancer Hospital

Recruiting

Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (Stars)

Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma

China
University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
Sun Yat-sen University

Not yet recruiting

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

Penile Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Toripalimab for High-risk Locally Advanced Cervical Cancer

Cervical Cancers

China
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer

Search clinical trials for: ineligible to cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations